The global Digital Therapeutic Devices Market size was estimated at USD 6,450.70 million in 2025 and is expected to reach USD 15,410.07 million by 2032, growing at a CAGR of 15.62% from 2025 to 2032. Growth is driven by rising chronic disease prevalence and the need to extend care beyond clinics through connected, outcomes-measurable therapeutic delivery supported by sensors, apps, and remote monitoring pathways. Wider acceptance of hybrid care models across provider and employer channels continues to accelerate adoption as therapeutic programs become more integrated with real-world data and longitudinal patient engagement.
REPORT ATTRIBUTE
DETAILS
Historical Period
2021-2024
Base Year
2025
Forecast Period
2026-2032
Digital Therapeutic Devices Market Size 2025
USD 6,450.70 million
Digital Therapeutic Devices Market, CAGR
15.62%
Digital Therapeutic Devices Market Size 2032
USD 15,410.07 million
Key Market Trends & Insights
The Digital Therapeutic Devices Market expands from USD 6,450.70 million (2025) to USD 15,410.07 million (2032), reflecting a 15.62% CAGR (2025–2032).
North America accounts for 41.7% revenue share in 2025, reflecting earlier commercialization and stronger channel readiness for connected therapeutic delivery.
Europe represents 31.6% revenue share in 2025, supported by structured care pathways and evidence-based adoption across healthcare systems.
Diabetes holds 33.8% share in 2025, reinforcing chronic care as a core demand center for connected therapeutic programs.
Prescription-based devices capture 31.1% share in 2025, highlighting the role of clinically guided distribution in scaling utilization.
Segment Analysis
Digital Therapeutic Devices Market demand reflects a shift toward measurable, behavior-linked interventions that combine device-derived signals with software-guided therapy. Wearables, app-connected medical devices, and sensor-based devices support continuous monitoring, adherence support, and personalization across chronic care pathways. Buyer priorities increasingly center on ease of onboarding, sustained engagement, interoperability with clinical workflows, and outcome traceability. Delivery models favor combinations of clinical oversight and scalable digital engagement as stakeholders pursue consistent results outside traditional care settings.
Indication-level adoption remains concentrated in conditions with high prevalence, long treatment horizons, and clear endpoints for improvement such as glycemic control, symptom management, and adherence. Diabetes leads due to strong monitoring needs and established connected ecosystem readiness, while mental health and cardiovascular support use cases benefit from structured coaching, biofeedback, and remote monitoring integration. Technology choices increasingly reflect the need to translate high-frequency data into actionable therapy decisions while maintaining clinical confidence and data governance readiness.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Wearable therapeutic devices, app-connected medical devices, and sensor-based devices gain adoption as healthcare delivery shifts toward continuous monitoring and home-based intervention support. Wearable form factors reduce user friction through passive data capture and routine integration during daily activity. App-connected peripherals strengthen adherence through reminders, coaching, and feedback loops tied to measurable outcomes. Sensor-enabled workflows also improve care continuity by enabling earlier detection of deterioration and more timely adjustments to therapeutic programs.
By Indication Insights
Diabetes accounted for the largest share of 33.8% in 2025. Diabetes leadership is supported by strong demand for continuous monitoring, adherence reinforcement, and behavior change programs aligned with measurable outcomes. Connected glucose monitoring and coaching workflows fit well with long-duration therapy needs and recurring engagement cycles. Broader integration with remote monitoring and care teams also supports sustained usage across preventive and management pathways.
By Technology Insights
AI-driven therapy, biofeedback systems, and connected sensors expand relevance as stakeholders emphasize personalization, engagement, and measurable outcomes. AI-driven approaches improve therapy precision by adapting interventions based on real-world signals and adherence patterns. Biofeedback systems support structured behavior change in stress, respiratory training, and rehabilitation contexts where feedback loops improve consistency. Connected sensors strengthen clinical confidence by improving data continuity, enabling timely escalation, and supporting standardized reporting.
By Delivery Model Insights
Prescription-based devices accounted for the largest share of 31.1% in 2025. Prescription-led distribution benefits from clearer clinical triggers, structured onboarding, and stronger provider confidence in evidence-backed claims. Reimbursement-linked pathways improve persistence by aligning follow-up routines and care-team involvement with longitudinal outcomes. Hybrid models expand reach where employers and payers blend clinician oversight with scalable digital engagement and remote monitoring support.
By End User Insights
Patients accounted for the largest share of 45.2% in 2025. Patient-led utilization grows as home-based therapeutic delivery reduces friction and supports consistent routines outside clinics. Patient-facing apps and connected devices improve adherence through coaching, reminders, and feedback, which strengthens engagement over long treatment periods. Demand also rises as healthcare systems seek scalable support for chronic care while maintaining outcome measurement and traceability.
Digital Therapeutic Devices Market Drivers
Expansion of chronic disease management outside clinical settings
Digital Therapeutic Devices Market growth is propelled by rising chronic disease burden and the need to extend care beyond hospitals and clinics. Connected devices enable continuous monitoring and support longitudinal therapeutic interventions in daily environments. Stakeholders prioritize solutions that improve adherence, reduce avoidable utilization, and support earlier escalation when symptoms change. Therapeutic delivery combined with real-world data improves confidence in outcomes and supports broader program adoption.
Improved access through remote monitoring and home-based care models
Digital Therapeutic Devices Market demand strengthens as remote monitoring becomes more embedded across care pathways. Home-based care models reduce operational load on providers while supporting continuity for patients with recurring needs. Connected sensors and app-linked workflows enable proactive interventions and more consistent follow-up. Care teams benefit from improved visibility into adherence and symptom trends, supporting more timely decision-making.
For instance, Lee Health’s remote patient monitoring program with Biofourmis reported a 50% reduction in 30-day readmissions and operates at an average daily census of more than 700 patients, while GE Healthcare materials on Biofourmis-enabled acute care at home cite a 1.56-day average length-of-stay reduction and 16,300 hospital patient days saved.
Clinical validation and outcomes measurement enabling wider adoption
Digital Therapeutic Devices Market adoption accelerates when products demonstrate measurable outcomes and align with evidence expectations. Stakeholders increasingly evaluate therapy programs based on adherence metrics, improvement indicators, and consistent reporting practices. Validation supports provider trust and improves channel readiness for prescription-led and enterprise procurement. Evidence-backed positioning also supports integration into structured clinical pathways and long-term utilization.
For instance, Welldoc’s BlueStar digital therapeutic has shown a 2.0-point mean A1C reduction in individuals with type 2 diabetes, and another randomized study cited a 1.9-point mean A1C reduction, providing a clearly quantified outcomes foundation for provider and payer adoption.
Growth of connected ecosystems and interoperability expectations
Digital Therapeutic Devices Market expansion is supported by broader availability of connected sensors, smartphones, and cloud-enabled analytics. Interoperability with clinical systems and patient tools becomes a differentiator as deployment scales across multi-site networks. Integration readiness reduces workflow friction and supports consistent data capture for performance monitoring. Ecosystem connectivity also enables personalization and supports iterative improvements in engagement and therapeutic effectiveness.
Digital Therapeutic Devices Market Challenges
Digital Therapeutic Devices Market scaling faces challenges related to sustained engagement and real-world adherence across diverse user populations. Many programs require long-duration participation, and engagement can decline without effective coaching and personalization. Data governance and privacy readiness also remain critical, particularly where cross-border compliance expectations vary. Integration complexity with clinical workflows can slow procurement and implementation when systems require customization and training.
For instance, Propeller reported that adults with uncontrolled asthma using its connected inhaler platform maintained 68% medication adherence at three months, while the standard-care group experienced a 17% decline, and the company states that its data can be accessed by healthcare professionals through a provider portal or API to support workflow integration.
Digital Therapeutic Devices Market adoption can also be constrained by uneven reimbursement, limited clinician time, and fragmented pathways across regions. Prescription and provider-led models require clear onboarding triggers and structured follow-up capacity. Evidence standards may differ across payers and public systems, leading to delays in scaling validated programs. Device affordability and access disparities can limit expansion in lower-resource settings despite strong demand fundamentals.
Digital Therapeutic Devices Market Trends and Opportunities
Digital Therapeutic Devices Market opportunity expands as hybrid models combine clinical oversight with scalable digital engagement. Stakeholders increasingly favor solutions that support remote monitoring, personalize interventions, and maintain measurable outcomes. Partnerships with providers, payers, and employers strengthen distribution and improve utilization persistence. Adoption also rises when solutions reduce operational burden through automation and decision support tied to patient data streams.
For instance, Hinge Health reported in a randomized controlled trial involving 162 participants recruited through employers that its 12-week home-based digital care program using wearable sensors delivered a 61% reduction in pain among program completers versus 21% in the control group, while perceived need for surgery within five years fell by 63% versus 17%, demonstrating measurable outcomes in an employer-linked distribution model.
Digital Therapeutic Devices Market momentum benefits from advancing AI-driven personalization and improved sensor fidelity across wearable and peripheral ecosystems. AI-driven therapy enables more adaptive pathways that respond to behavioral signals, symptom trends, and adherence patterns. Biofeedback-enabled programs expand applications in stress, respiratory training, and rehabilitation. Broader integration across homecare settings creates opportunities for end-to-end therapeutic workflows aligned with longitudinal care strategies.
Regional Insights
North America
Digital Therapeutic Devices Market leadership in North America reflects earlier commercialization, stronger channel readiness, and scalable distribution through employer, payer, and provider pathways. North America held 41.7% revenue share in 2025, supported by higher willingness to adopt regulated digital care and integrated remote monitoring models. Procurement decisions prioritize evidence, integration, and workflow traceability across multi-site networks. Adoption accelerates when solutions demonstrate consistent outcomes and support hybrid care delivery across chronic conditions.
Europe
Digital Therapeutic Devices Market adoption in Europe is shaped by structured healthcare systems and evidence-first validation expectations. Europe captured 31.6% revenue share in 2025 as national programs and reimbursement pathways support growth where clinical value is demonstrated. Buyers focus on compliance readiness, interoperability, and long-term operating efficiency. Adoption benefits from regional care networks that seek standardized workflows and consistent outcome reporting.
Asia Pacific
Digital Therapeutic Devices Market growth in Asia Pacific is supported by large addressable populations, increasing digital health investment, and mobile-first onboarding. Asia Pacific represented 15.4% revenue share in 2025, with demand driven by expanding chronic disease management needs and improving access to connected devices. Commercialization strategies often emphasize scalability and patient engagement to address care capacity gaps. Variation in reimbursement and data governance across countries influences deployment models and partner selection.
Latin America
Digital Therapeutic Devices Market expansion in Latin America is influenced by growing chronic disease burden and improving smartphone penetration, while reimbursement and channel fragmentation remain constraints. Latin America accounted for 5.8% revenue share in 2025, with demand concentrated in larger health systems and urban networks. Adoption improves when solutions fit employer-sponsored care programs and private provider models. Integration simplicity and affordability remain important for broader scale across diverse healthcare infrastructures.
Middle East & Africa
Digital Therapeutic Devices Market adoption in the Middle East & Africa advances where public digital health initiatives and private provider modernization support connected care. Middle East & Africa held 5.5% revenue share in 2025, with momentum strongest in markets investing in digital infrastructure and remote monitoring pathways. Implementation often prioritizes chronic disease management and home-based care continuity. Data governance readiness and procurement standardization continue to shape scaling pace across sub-regions.
Competitive Landscape
Digital Therapeutic Devices Market competition is shaped by clinical validation strength, engagement performance, and integration readiness with connected sensors and healthcare workflows. Vendors differentiate through condition-specific program depth, personalization capability, and ability to demonstrate measurable outcomes over time. Enterprise distribution strategies increasingly emphasize partnerships with payers, employers, and provider networks to improve utilization persistence. Product portfolios also evolve toward hybrid models that combine device signals with software-guided therapy and remote monitoring support.
Omada Health positions Digital Therapeutic Devices Market offerings around scalable chronic condition programs supported by structured coaching, behavior change workflows, and outcomes reporting aligned with enterprise buyer expectations. Omada Health leverages data-driven personalization to improve adherence and long-term engagement across prevention and management pathways. Omada Health channel strategy typically aligns with employer and payer distribution where measurable results support contracting. Omada Health also benefits from ecosystem partnerships that strengthen onboarding, remote monitoring integration, and longitudinal member support.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Omada Health
Livongo (Teladoc)
Propeller Health
Biofourmis
Voluntis
Medtronic
ResMed
Dexcom
Noom
Hinge Health
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Developments
In April 2025, Click Therapeutics announced FDA marketing authorization for CT-132, a prescription digital therapeutic for the preventive treatment of episodic migraine in adults in the U.S. This marked an important new product milestone in the market because CT-132 was described as the first prescription digital therapeutic for that indication.
In March 2025, ATA Action, the advocacy arm of the American Telemedicine Association, acquired the Digital Therapeutics Alliance (DTA). This acquisition created a broader platform for digital health policy and advocacy, with digital therapeutics remaining one of the priority focus areas of the combined organization
In February 2025, Hyfe, Inc. entered a partnership with KYORIN Pharmaceutical Co., Ltd. to develop and commercialize a prescription digital therapeutic for chronic cough in Japan. The collaboration is positioned as a major digital therapeutics partnership focused on expanding access to chronic cough treatment through AI-powered respiratory care technology.
In February 2025, XRHealth announced the acquisition of RealizedCare, an immersive digital therapeutics company focused on chronic pain and mental health solutions. The deal expanded XRHealth’s AI-driven therapeutic XR platform by adding RealizedCare’s evidence-based digital therapeutics programs and triage capabilities.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 6,450.70 million
Revenue forecast in 2032
USD 15,410.07 million
Growth rate (CAGR)
15.62% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Device Type; By Indication; By Technology; By Delivery Model; By End User
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled
Omada Health; Livongo (Teladoc); Propeller Health; Biofourmis; Voluntis; Medtronic; ResMed; Dexcom; Noom; Hinge Health
No. of Pages
328
Segmentation
By Device Type
Wearable Therapeutic Devices
App-connected Medical Devices
Sensor-based Devices
Others
By Indication
Diabetes
Cardiovascular Disorders
Mental Health
Respiratory Diseases
Others
By Technology
AI-driven Therapy
Biofeedback Systems
Connected Sensors
Others
By Delivery Model
Prescription-based Devices
OTC Devices
Hybrid Models
Others
By End-User
Patients
Hospitals
Homecare Settings
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Table of Contents (The complete Toc, LoF and LoT are available in the sample report)
1. Introduction
1.1 Report Description
1.2 Purpose of the Report
1.3 USP & Key Offerings
1.4 Key Benefits for Stakeholders
1.5 Target Audience
1.6 Report Scope
1.7 Regional Scope 2. Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology 3. Executive Summary 4. Introduction
4.1 Overview
4.2 Key Industry Trends 5. Global Digital Therapeutic Devices Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast 6. Market Breakup by Device Type
6.1 Wearable Therapeutic Devices
6.1.1 Market Trends
6.1.2 Market Forecast
6.1.3 Revenue Share
6.1.4 Revenue Growth Opportunity
6.2 App-connected Medical Devices
6.2.1 Market Trends
6.2.2 Market Forecast
6.2.3 Revenue Share
6.2.4 Revenue Growth Opportunity
6.3 Sensor-based Devices
6.3.1 Market Trends
6.3.2 Market Forecast
6.3.3 Revenue Share
6.3.4 Revenue Growth Opportunity
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
6.4.3 Revenue Share
6.4.4 Revenue Growth Opportunity 7. Market Breakup by Indication
7.1 Diabetes
7.1.1 Market Trends
7.1.2 Market Forecast
7.1.3 Revenue Share
7.1.4 Revenue Growth Opportunity
7.2 Cardiovascular Disorders
7.2.1 Market Trends
7.2.2 Market Forecast
7.2.3 Revenue Share
7.2.4 Revenue Growth Opportunity
7.3 Mental Health
7.3.1 Market Trends
7.3.2 Market Forecast
7.3.3 Revenue Share
7.3.4 Revenue Growth Opportunity
7.4 Respiratory Diseases
7.4.1 Market Trends
7.4.2 Market Forecast
7.4.3 Revenue Share
7.4.4 Revenue Growth Opportunity
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
7.5.3 Revenue Share
7.5.4 Revenue Growth Opportunity 8. Market Breakup by Technology
8.1 AI-driven Therapy
8.1.1 Market Trends
8.1.2 Market Forecast
8.1.3 Revenue Share
8.1.4 Revenue Growth Opportunity
8.2 Biofeedback Systems
8.2.1 Market Trends
8.2.2 Market Forecast
8.2.3 Revenue Share
8.2.4 Revenue Growth Opportunity
8.3 Connected Sensors
8.3.1 Market Trends
8.3.2 Market Forecast
8.3.3 Revenue Share
8.3.4 Revenue Growth Opportunity
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
8.4.3 Revenue Share
8.4.4 Revenue Growth Opportunity 9. Market Breakup by Delivery Model
9.1 Prescription-based Devices
9.1.1 Market Trends
9.1.2 Market Forecast
9.1.3 Revenue Share
9.1.4 Revenue Growth Opportunity
9.2 OTC Devices
9.2.1 Market Trends
9.2.2 Market Forecast
9.2.3 Revenue Share
9.2.4 Revenue Growth Opportunity
9.3 Hybrid Models
9.3.1 Market Trends
9.3.2 Market Forecast
9.3.3 Revenue Share
9.3.4 Revenue Growth Opportunity
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
9.4.3 Revenue Share
9.4.4 Revenue Growth Opportunity 10. Market Breakup by End User
10.1 Patients
10.1.1 Market Trends
10.1.2 Market Forecast
10.1.3 Revenue Share
10.1.4 Revenue Growth Opportunity
10.2 Hospitals
10.2.1 Market Trends
10.2.2 Market Forecast
10.2.3 Revenue Share
10.2.4 Revenue Growth Opportunity
10.3 Homecare Settings
10.3.1 Market Trends
10.3.2 Market Forecast
10.3.3 Revenue Share
10.3.4 Revenue Growth Opportunity
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
10.4.3 Revenue Share
10.4.4 Revenue Growth Opportunity 11. Market Breakup by Region
11.1 North America
11.1.1 United States
11.1.1.1 Market Trends
11.1.1.2 Market Forecast
11.1.2 Canada
11.1.2.1 Market Trends
11.1.2.2 Market Forecast
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 United Kingdom
11.2.4 Italy
11.2.5 Spain
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Rest of Asia-Pacific
11.4 Latin America
11.4.1 Brazil
11.4.2 Mexico
11.4.3 Rest of Latin America
11.5 Middle East & Africa
11.5.1 Market Trends
11.5.2 Market Breakup by Country
11.5.3 Market Forecast 12. SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats 13. Value Chain Analysis 14. Porter’s Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes 15. Price Analysis 16. Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Omada Health
16.3.1.1 Company Overview
16.3.1.2 Product Portfolio
16.3.1.3 Financials
16.3.1.4 SWOT Analysis
16.3.2 Livongo (Teladoc)
16.3.3 Propeller Health
16.3.4 Biofourmis
16.3.5 Voluntis
16.3.6 Medtronic
16.3.7 ResMed
16.3.8 Dexcom
16.3.9 Noom
16.3.10 Hinge Health 17. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size and forecast for the Digital Therapeutic Devices Market?
The Digital Therapeutic Devices Market was valued at USD 6,450.70 million in 2025. The Digital Therapeutic Devices Market is projected to reach USD 15,410.07 million by 2032.
What is the CAGR for the Digital Therapeutic Devices Market?
The Digital Therapeutic Devices Market is expected to grow at a CAGR of 15.62% from 2025 to 2032. Growth reflects expanding adoption of connected therapeutic delivery models.
What is the largest segment in the Digital Therapeutic Devices Market?
Diabetes is the largest indication segment with a 33.8% share in 2025. Diabetes leadership is supported by continuous monitoring and adherence-focused therapeutic programs.
What factors are driving growth in the Digital Therapeutic Devices Market?
Key drivers include chronic disease burden, remote monitoring expansion, and demand for measurable outcomes. Integration of sensors with software-guided therapy also supports broader adoption.
Who are the leading companies in the Digital Therapeutic Devices Market?
Leading companies include Omada Health, Livongo (Teladoc), Propeller Health, Biofourmis, and Voluntis. Additional key players include Medtronic, ResMed, Dexcom, Noom, and Hinge Health.
Which region leads the Digital Therapeutic Devices Market?
North America leads the Digital Therapeutic Devices Market with a 41.7% share in 2025. Europe follows with a 31.6% share in 2025.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The North America Cardiovascular Drugs Market size was valued at USD 35,146.60 MN in 2021 and reached USD 46,140.28 MN in 2025. It is anticipated to reach USD 70,300.43 MN by 2032, growing at a CAGR of 5.01% during the forecast period.
The North America Anticancer Drugs/Oncology Drugs Market size was valued at USD 64,394.03 MN in 2021 and reached USD 87,086.19 MN in 2025. It is anticipated to reach USD 150,370.53 MN by 2032, growing at a CAGR of 6.76% during the forecast period.
The DNA Forensics Market size was estimated at USD 6,940.47 million in 2025 and is expected to reach USD 11,601.47 million by 2032, growing at a CAGR of 8.94% from 2025 to 2032.
The global healthcare POS terminals market was valued at USD 16,218 million in 2024 and is projected to reach USD 35,840.49 million by 2032, expanding at a compound annual growth rate (CAGR) of 10.42% during the forecast period, according to Credence Research.
The global healthcare analytical testing market was valued at USD 8,183 million in 2024 and is projected to reach USD 18,870.73 million by 2032, expanding at a compound annual growth rate (CAGR) of 11.01% during the forecast period,
The Global Optogenetics market size was valued at USD 118 million in 2024 and is anticipated to reach USD 180.24 million by 2032, growing at a CAGR of 5.46% during the forecast period.
The glycated albumin assay market was valued at USD 613 million in 2024 and is projected to reach USD 1,135.21 million by 2032, registering a CAGR of 8% during the forecast period.
The pregelatinized starch market reached USD 3,344.5 million in 2024 and is projected to reach USD 4,626.7 million by 2032, growing at a CAGR of 4.14% during the forecast period. (Credence Research)
The pregnancy detection kits market reached USD 1,694.5 million in 2024 and is projected to reach USD 2,541.95 million by 2032, growing at a CAGR of 5.2% during the forecast period.
The Magnetic Resonance Imaging (MRI) market was valued at USD 7094.5 million in 2024 and is anticipated to reach USD 11566.13 million by 2032, growing at a CAGR of 6.3% during the forecast period.
Cell Cytometry market size was valued USD 5,659 Million in 2024 and is anticipated to reach USD 10,319.51 Million by 2032, at a CAGR of 7.8% during the forecast period.
Blood Meal Market size was valued USD 8,920 Million in 2024 and is anticipated to reach USD 14,542.23 Million by 2032, at a CAGR of 6.3% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
